Policy & Strategy
National biomanufacturing strategies and public investment — GFI, India's BioE3, the US Bioeconomy initiative, the EU Biotech Act and more.
Latest Policy & Strategy news
Plant-based food industry evolution: how a new alternative became a global standard
Read at Hospitality Net →GFI: Biomass fermentation proteins generate 98% fewer emissions than beef
Read at Dairynews.today →Does the Future of Food Production Start in the Lab?
Read at Food Manufacturing →Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies
Read at PR Newswire →Accelerating the Bio Economy: How Singapore-based startup Allozymes is developing the Google of Enzymes
Read at Singapore Economic Development Board (EDB) →How Singapore is transforming its energy and chemicals sector
Read at Singapore Economic Development Board (EDB) →From the knowledge base
StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance
Shares of gene editing therapy companies mostly surged this past week on two growth catalysts: Data readouts at the European Society of Gene and Cell Therapy’s 33rd ESGCT Annual Congress, and the FDA's new draft guidance for personalized gene therapies.
How the NEXTY Awards open doors to valuable food service partnerships
Corporate food service providers offer bulk purchases, direct feedback and exposure to thousands of consumers. Here's how the NEXTY Awards can help you break in.
Anthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and more
Hello and welcome back to a spooky Halloween edition of Endpoints Weekly! Sorry to all the candy corn lovers out there, but just noting that they’re actually made with bug secretions. The Atlantic has all ...
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
According to the company, the funds will support the next phase of its growth in enabling autonomous science in labs and biopharmaceutical companies using its AI and robotics systems.
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Parse Biosciences and Nomic Bio are partnering to create Cascade, a 100-million-cell multimodal dataset combining single-cell and proteomic data to advance AI-driven immune modeling, drug discovery, and therapeutic target identification.
Sanofi may seek higher European drug prices, not withhold launches, under Trump deal
While some of Europe’s biggest drugmakers have warned that President Donald Trump’s pricing policies could leave European patients waiting longer for new medicines, Sanofi is taking a different approach. ...